Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials

Topics: 

Citation
Aroda VR et al. Diabetes Metab 2019;45(5):409-418.